Good morning

Eugia Pharma Receives USFDA Approval for Daptomycin for Injection 500mg

Published: September 02, 2021

Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Daptomycin for Injection 500 mg.

Indications for this product include:

  • Complicated skin and skin structure infections;
  • Staphylococcus aureus bloodstream infections (bacteremia) in adult patients;
  • Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients.

Refer to package insert for full prescribing information.